Skip to content

Human Anaplasmosis in Eastern France

Epidemiology and Clinical Presentation of Human Anaplasmosis in Eastern France

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01013636
Enrollment
300
Registered
2009-11-16
Start date
2009-11-30
Completion date
Unknown
Last updated
2011-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaplasmosis, Ehrlichia, Tick-borne Disease

Brief summary

Anaplasmosis is a tick-borne transmitted infection. Its clinical expression include fever, cytopenia and hepatitis.This infection was initially described in United States. In Europe, its epidemiology is not well known. Some isolated cases have been diagnosed in several country, were the tick Ixodes ricinus is known to transmitted another infection :the Lyme borreliosis.The purpose of our study is to look systematically for Anaplasmosis, in patient living in Eastern France, and presenting with compatible clinical symptoms using a new diagnosis tool : PCR in blood samples. So we will have new data about epidemiology in our country and the clinical symptoms that are associated with Anaplasmosis.

Interventions

PROCEDUREBlood sampling

* Anaplasma diagnosis test : serology and PCR * If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patient with at least one of following symptoms : fever or muscular pain or articular pain or respiratory signs or neurological signs or meningitis or erythema occurring during the three weeks after a tick bite- * Or * patient with fever with at least one of following criteria : thrombocytopenia, leucopenia, hepatitis, without any other cause that can explain these abnormalities. * Or * patient with tick-borne encephalitis, or primary stage Lyme borreliosis

Exclusion criteria

* children less that 10 years * pregnancy * patients with an other diagnosis that can explain clinical symptoms or biological abnormalities * antibiotherapy with cyclins during the days before inclusion

Design outcomes

Primary

MeasureTime frame
Risk factor, clinical and biological markers of infection for patients with Anaplasma antibody seroconversion6 weeks

Countries

France

Contacts

Primary ContactYves HANSMANN, MD
yves.hansmann@chru-strasbourg.fr33.3.69.55.05.45

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026